Name: Ticagrelor Market Regional Analysis
Creator: Coherent Market Insights
License: https://www.coherentmarketinsights.com/privacy-policy
Keywords: Ticagrelor Market, Ticagrelor Market Report, Ticagrelor Industry Report, Ticagrelor Market Size, Ticagrelor Market Share, Ticagrelor Market Analysis, Ticagrelor Market Growth, Ticagrelor Market Trends, Ticagrelor Market Overview, Ticagrelor Market Forecast

Ticagrelor Market, by Strength (60 mg, and 90 mg), by Indication (Acute Coronary Syndrome, and Ischemic Stroke), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Size, Share, Outlook, and Opportunity Analysis, 2018-2026

Published In : Feb 2019

Code : CMI2515

Pages :157

Formats :

Excel and PDF

Industry : Pharmaceutical

Regional Analysis

Ticagrelor Market- Regional Analysis

Regional segmentation of the global ticagrelor market comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America holds the chief stake in the ticagrelor market, owing to increase in mergers and acquisitions of key players. For instance, in November 2017, PhaseBio Pharmaceuticals, Inc. entered into an exclusive, worldwide license agreement with MedImmune, the global biologics research and development arm of AstraZeneca, for PB2452 (formerly MEDI2452), a phase 1-ready reversal agent for ticagrelor. Ticagrelor binds reversibly with the receptors present on platelets.

Europe is also expected to observe significant growth in the global ticagrelor market, owing to increasing approvals for new ticagrelor formulation development in the region. For instance, in May 2017, the European Commission granted marketing authorization for AstraZeneca’s Brilique (ticagrelor) orodispersible tablets (ODT) as a new method of treatment administration. This tablet is effective for patients with difficulty in swallowing and in emergency cases.